PsorX (CE-IVD) – a breakthrough for inflammatory skin diseases
PsorX detects the molecular signature of psoriasis versus eczema supporting the reliable differential diagnosis of these diseases.
Based on the gene expression of NOS2 and CCL27, PsorX accurately and efficiently distinguishes these diseases, even in cases where conventional diagnostic methods failed¹’
Psoriasis
“Significant knowledge regarding psoriasis and advancement in psoriasis treatment have been gained over the past 30 years. Despite this, in review of the currently available highest level of evidence, the expert work group acknowledges that much has yet to be learned…There is also an important need to identify biomarkers that can potentially predict the appropriate biologic agent for individual patients.” ³
Background
Psoriasis and atopic dermatitis are the most common inflammatory diseases. However, up to 50 % of patients with psoriasis and eczema pose diagnostic challenges due to substantial overlap in clinical and histopathologic presentation⁴. Therefore, modern biologicals and small-molecule inhibitors tailored for either psoriasis or eczema fall short of their therapeutic potential and cause severe side-effects. Dermagnostix offers molecular diagnostic solutions to meet the need for personalized care. Simply. And at the point of need.
By loading the video, you agree to YouTube's privacy policy.
Learn more
Pipeline products
Novel LabDisk tests in our biomarker pipeline address clinical questions to provide comprehensive diagnostics in dermatology.
LymphX
Dermagnostix gene expression based LabDisk test will enable the differential diagnosis of mycosis fungoides (MF), psoriasis, and eczema. Accurate and early diagnosis is needed to improve patients’ quality of life and overall life expectancy.
Background
The most common form of cutaneous t-cell lymphoma (CTCL), mycosis fungoides (MF), is a malignant tumor of the skin that often presents as a red rash. Using conventional methods, MF can rarely be differentiated from inflammatory diseases such as eczema in the initial stages. Adjunct techniques such as T-cell clonality analysis are of limited advantage.
“The diagnosis of early MF (patch stage) is particularly challenging […] This diagnosis might be elusive because MF in its early stage shares clinical and histopathological features with inflammatory benign dermatoses…and immunohistochemistry and molecular analysis have limited utility as isolated criteria" ⁷
PatternX
Dermagnostix’ gene-expression-based panel of inflammatory disease markers enables phenotypic characterization of disease, biomarker characterization and the identification of disease subsets. PatternX can also support the development of complementary and companion diagnostics and the stratification and selection of patients in clinical research studies.
Background
There is a need for timely and cost-efficient identification of molecular biomarkers in research and clinical development to inform target selection, drug candidate selection and to understand the mechanism of action. Biomarkers are valuable tools for drug discovery and development.
“Utilization of biomarkers has a potential to make drug discovery, development and approval processes more efficient.” ⁵
PsorX 2.0
PsorX 2.0 is for the differential diagnosis of psoriasis, eczema and tinea. The use of a non-invasive sampling method (e.g. scraping or skin tape) enables dermatologists to use the test directly at the point-of-care in their practice, providing results of the highest molecular biological quality even more quickly.
References
- Garzorz-Stark N, Krause L, Lauffer F, Atenhan A, Thomas J, Stark SP, Franz R, Weidinger S, Balato A, Mueller NS, Theis FJ, Ring J, Schmidt-Weber CB, Biedermann T, Eyerich S, Eyerich K (2016): A novel molecular disease classifier for psoriasis and eczema. Experimental Dermatology 25(10): 767-774.
- Quaranta M, Knapp B, Garzorz-Stark N, Mattii M, Pullabhatla V, Pennino D, Andres C, Traidl-Hoffmann C, Cavani A, Theis F, Ring J, Schmidt-Weber C, Eyerich S, Eyerich K (2014): Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema. Science translational medicine 6(244): 244ra90-244ra90.
- Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Elmets CA (2019): Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology 80(4): 1029-1072.
- Kolesnik M, Franke I, Lux A, Quist S, Gollnick HP (2018): Eczema in psoriatico: An important differential diagnosis between chronic allergic contact dermatitis and psoriasis in palmoplantar localization. Acta Dermato-Venereologica 98(1): 50-58.
- Gromova M, Vaggelas A, Dallmann G, Seimetz D (2020): Biomarkers: opportunities and challenges for drug development in the current regulatory landscape. Biomarker Insights 15: 1177271920974652.
- Ujiie H, Rosmarin D, Schön MP, Ständer S, Boch K, Metz M, Thaci D, Schmidt E, Cole C, Amber KT, Didona D, Hertl M, Recke A, Grasshoff H, Hackel A, Schumann A, Riemekasten G, Bieber K, Sprow G, Dan J, Zillikens D, Sezin T, Christiano AM, Wolk K, Sabat R, Kridin K, Werth VP, Ludwig RJ (2022): Unmet medical needs in chronic, non-communicable inflammatory skin diseases. Frontiers in medicine 9:875492.
- Torres-Cabala CA (2020): Diagnosis of T-cell lymphoid proliferations of the skin: putting all the pieces together. Modern Pathology 33:83-95.